CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,021,955 | +4.2% | 37,135 | +28.5% | 0.00% | – |
Q2 2023 | $980,916 | -71.3% | 28,910 | -69.6% | 0.00% | -100.0% |
Q1 2023 | $3,423,713 | +0.4% | 95,156 | +24.4% | 0.00% | 0.0% |
Q4 2022 | $3,408,803 | +614.6% | 76,482 | +350.5% | 0.00% | – |
Q3 2022 | $477,000 | -11.5% | 16,977 | -15.0% | 0.00% | – |
Q2 2022 | $539,000 | -12.5% | 19,974 | +10.2% | 0.00% | – |
Q1 2022 | $616,000 | -92.3% | 18,123 | -91.3% | 0.00% | -100.0% |
Q4 2021 | $8,025,000 | -72.2% | 207,672 | -61.1% | 0.00% | -71.4% |
Q3 2021 | $28,830,000 | +100.3% | 533,985 | +24.1% | 0.01% | +75.0% |
Q2 2021 | $14,392,000 | +168.2% | 430,407 | +65.2% | 0.00% | +300.0% |
Q1 2021 | $5,366,000 | -32.3% | 260,495 | -51.3% | 0.00% | -66.7% |
Q3 2020 | $7,928,000 | +8909.1% | 534,584 | +1257.0% | 0.00% | – |
Q4 2019 | $88,000 | -1.1% | 39,394 | -6.2% | 0.00% | – |
Q3 2019 | $89,000 | -23.9% | 41,997 | -3.8% | 0.00% | – |
Q2 2019 | $117,000 | -47.3% | 43,641 | -3.3% | 0.00% | – |
Q1 2019 | $222,000 | – | 45,148 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |